Enanta Pharmaceuticals, Inc. (ENTA) News

Enanta Pharmaceuticals, Inc. (ENTA): $12.13

0.93 (-7.12%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

C

Add ENTA to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#105 of 362

in industry

Filter ENTA News Items

ENTA News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ENTA News Highlights

  • ENTA's 30 day story count now stands at 3.
  • Over the past 7 days, the trend for ENTA's stories per day has been choppy and unclear. It has oscillated between 1 and 1.

Latest ENTA News From Around the Web

Below are the latest news stories about ENANTA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ENTA as an investment opportunity.

The Zacks Analyst Blog Highlights Enanta, OneConnect Financial, KNOT Offshore, Hippo Holdings and H World

Enanta, OneConnect Financial, KNOT Offshore, Hippo Holdings and H World are included in this Analyst Blog.

Yahoo | December 20, 2023

Insider Sell Alert: Director Terry Vance Sells 15,295 Shares of Enanta Pharmaceuticals Inc (ENTA)

In a notable insider transaction, Director Terry Vance has parted with 15,295 shares of Enanta Pharmaceuticals Inc (NASDAQ:ENTA), a significant move that warrants a closer look by investors and market analysts.

Yahoo | December 16, 2023

Wall Street Analysts Predict a 108.12% Upside in Enanta Pharmaceuticals (ENTA): Here's What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 108.1% in Enanta Pharmaceuticals (ENTA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Yahoo | December 13, 2023

How Much Upside is Left in Enanta Pharmaceuticals (ENTA)? Wall Street Analysts Think 88.23%

The mean of analysts' price targets for Enanta Pharmaceuticals (ENTA) points to an 88.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Yahoo | November 27, 2023

Enanta Pharmaceuticals to Participate at Evercore ISI HealthCONx Conference

WATERTOWN, Mass., November 22, 2023--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs with an emphasis on treatments for viral infections, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at Evercore ISI HealthCONx Conference on November 29, 2023 at 7:55 a.m. ET in Miami, FL.

Yahoo | November 22, 2023

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q4 2023 Earnings Call Transcript

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q4 2023 Earnings Call Transcript November 20, 2023 Enanta Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-1.33, expectations were $-2.11. Operator: Good afternoon, and welcome to Enanta Pharmaceuticals Fiscal Fourth Quarter and Year-End Financial Results Conference Call. At this time, all participants are in a listen-only mode. There will be […]

Yahoo | November 21, 2023

Q4 2023 Enanta Pharmaceuticals Inc Earnings Call

Q4 2023 Enanta Pharmaceuticals Inc Earnings Call

Yahoo | November 21, 2023

Enanta Pharmaceuticals Inc (ENTA) Reports Fiscal Q4 and Full-Year Earnings Amid R&D Focus

Revenue Declines as Company Advances Clinical Programs and Reduces Spending

Yahoo | November 20, 2023

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2023, with Webcast and Conference Call Today at 4:30 p.m. ET

WATERTOWN, Mass., November 20, 2023--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs with an emphasis on treatments for viral infections, today reported financial results for its fiscal fourth quarter and year ended September 30, 2023.

Yahoo | November 20, 2023

Analysts Estimate Enanta Pharmaceuticals (ENTA) to Report a Decline in Earnings: What to Look Out for

Enanta Pharmaceuticals (ENTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | November 13, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!